About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Inflammatory Bowel Disease Treatment Market Size, Top Share, Forecast to 2031
Inflammatory Bowel Disease Treatment Market

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn’s Disease, Ulcerative Colitis), By Drug Class (Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Others), By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRHI55443DR
Last Updated : November 14, 2024
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Inflammatory Bowel Disease Treatment Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Crohn’s Disease
        1. By Value
      3. Ulcerative Colitis
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Aminosalicylates
        1. By Value
      3. Corticosteroids
        1. By Value
      4. TNF inhibitors
        1. By Value
      5. IL inhibitors
        1. By Value
      6. Anti-integrin
        1. By Value
      7. JAK inhibitors
        1. By Value
      8. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Injectable
        1. By Value
      3. Oral
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Pharmacy
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Crohn’s Disease
        1. By Value
      3. Ulcerative Colitis
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Aminosalicylates
        1. By Value
      3. Corticosteroids
        1. By Value
      4. TNF inhibitors
        1. By Value
      5. IL inhibitors
        1. By Value
      6. Anti-integrin
        1. By Value
      7. JAK inhibitors
        1. By Value
      8. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Injectable
        1. By Value
      3. Oral
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Pharmacy
        1. By Value
    6. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Crohn’s Disease
          1. By Value
        3. Ulcerative Colitis
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Aminosalicylates
          1. By Value
        3. Corticosteroids
          1. By Value
        4. TNF inhibitors
          1. By Value
        5. IL inhibitors
          1. By Value
        6. Anti-integrin
          1. By Value
        7. JAK inhibitors
          1. By Value
        8. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Injectable
          1. By Value
        3. Oral
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Pharmacy
          1. By Value
    7. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Crohn’s Disease
        1. By Value
      3. Ulcerative Colitis
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Aminosalicylates
        1. By Value
      3. Corticosteroids
        1. By Value
      4. TNF inhibitors
        1. By Value
      5. IL inhibitors
        1. By Value
      6. Anti-integrin
        1. By Value
      7. JAK inhibitors
        1. By Value
      8. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Injectable
        1. By Value
      3. Oral
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Pharmacy
        1. By Value
    6. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Crohn’s Disease
          1. By Value
        3. Ulcerative Colitis
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Aminosalicylates
          1. By Value
        3. Corticosteroids
          1. By Value
        4. TNF inhibitors
          1. By Value
        5. IL inhibitors
          1. By Value
        6. Anti-integrin
          1. By Value
        7. JAK inhibitors
          1. By Value
        8. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Injectable
          1. By Value
        3. Oral
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Pharmacy
          1. By Value
    7. Germany
    8. France
    9. Spain
    10. Italy
    11. Russia
    12. Nordic
    13. Benelux
    14. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Crohn’s Disease
        1. By Value
      3. Ulcerative Colitis
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Aminosalicylates
        1. By Value
      3. Corticosteroids
        1. By Value
      4. TNF inhibitors
        1. By Value
      5. IL inhibitors
        1. By Value
      6. Anti-integrin
        1. By Value
      7. JAK inhibitors
        1. By Value
      8. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Injectable
        1. By Value
      3. Oral
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Pharmacy
        1. By Value
    6. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Crohn’s Disease
          1. By Value
        3. Ulcerative Colitis
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Aminosalicylates
          1. By Value
        3. Corticosteroids
          1. By Value
        4. TNF inhibitors
          1. By Value
        5. IL inhibitors
          1. By Value
        6. Anti-integrin
          1. By Value
        7. JAK inhibitors
          1. By Value
        8. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Injectable
          1. By Value
        3. Oral
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Pharmacy
          1. By Value
    7. Korea
    8. Japan
    9. India
    10. Australia
    11. Singapore
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Crohn’s Disease
        1. By Value
      3. Ulcerative Colitis
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Aminosalicylates
        1. By Value
      3. Corticosteroids
        1. By Value
      4. TNF inhibitors
        1. By Value
      5. IL inhibitors
        1. By Value
      6. Anti-integrin
        1. By Value
      7. JAK inhibitors
        1. By Value
      8. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Injectable
        1. By Value
      3. Oral
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Pharmacy
        1. By Value
    6. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Crohn’s Disease
          1. By Value
        3. Ulcerative Colitis
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Aminosalicylates
          1. By Value
        3. Corticosteroids
          1. By Value
        4. TNF inhibitors
          1. By Value
        5. IL inhibitors
          1. By Value
        6. Anti-integrin
          1. By Value
        7. JAK inhibitors
          1. By Value
        8. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Injectable
          1. By Value
        3. Oral
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Pharmacy
          1. By Value
    7. Turkey
    8. Saudi Arabia
    9. South Africa
    10. Egypt
    11. Nigeria
    12. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Crohn’s Disease
        1. By Value
      3. Ulcerative Colitis
        1. By Value
    3. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Aminosalicylates
        1. By Value
      3. Corticosteroids
        1. By Value
      4. TNF inhibitors
        1. By Value
      5. IL inhibitors
        1. By Value
      6. Anti-integrin
        1. By Value
      7. JAK inhibitors
        1. By Value
      8. Others
        1. By Value
    4. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Injectable
        1. By Value
      3. Oral
        1. By Value
    5. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Hospital Pharmacy
        1. By Value
      3. Retail Pharmacy
        1. By Value
      4. Online Pharmacy
        1. By Value
    6. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Crohn’s Disease
          1. By Value
        3. Ulcerative Colitis
          1. By Value
      2. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Aminosalicylates
          1. By Value
        3. Corticosteroids
          1. By Value
        4. TNF inhibitors
          1. By Value
        5. IL inhibitors
          1. By Value
        6. Anti-integrin
          1. By Value
        7. JAK inhibitors
          1. By Value
        8. Others
          1. By Value
      3. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Injectable
          1. By Value
        3. Oral
          1. By Value
      4. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Hospital Pharmacy
          1. By Value
        3. Retail Pharmacy
          1. By Value
        4. Online Pharmacy
          1. By Value
    7. Mexico
    8. Argentina
    9. Chile
    10. Colombia
    11. Rest of LATAM
    1. Inflammatory Bowel Disease Treatment Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. AbbVie Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Takeda Pharmaceutical Company Limited
    3. Pfizer Inc
    4. Biogen
    5. Novartis AG, Lilly
    6. UCB S.A.
    7. Merck & Co., Inc
    8. Johnson & Johnson Services, Inc.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global Fabry disease treatment market size was valued at USD 1,767.52 million in 2022. It is projected to reach USD 3,443.61 million by 2031, registering a CAGR of 6.9% during the forecast period (2023-2031). Factors such as rising
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.